Vol 26, No 1 (2019)
Letter to the Editor
Published online: 2019-03-14

open access

Page views 2745
Article views/downloads 1434
Get Citation

Connect on Social Media

Connect on Social Media

Uric acid and xantine-oxidase inhibitors in patients with gout: A re-assessment and an update

Claudio Borghi1, Krzysztof Narkiewicz2, Giuseppe Mancia3
Pubmed: 30882192
Cardiol J 2019;26(1):99-101.

Abstract

Not available

Article available in PDF format

View PDF Download PDF file

References

  1. Kuo CF, Grainge MJ, Zhang W, et al. Global epidemiology of gout: prevalence, incidence and risk factors. Nat Rev Rheumatol. 2015; 11(11): 649–662.
  2. Johnson RJ, Bakris GL, Borghi C, et al. Hyperuricemia, Acute and Chronic Kidney Disease, Hypertension, and Cardiovascular Disease: Report of a Scientific Workshop Organized by the National Kidney Foundation. Am J Kidney Dis. 2018; 71(6): 851–865.
  3. Bardin T, Richette P. Definition of hyperuricemia and gouty conditions. Curr Opin Rheumatol. 2014; 26(2): 186–191.
  4. Johnson RJ, Titte S, Cade JR, et al. Uric acid, evolution and primitive cultures. Semin Nephrol. 2005; 25(1): 3–8.
  5. Richette P, Doherty M, Pascual E, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2017; 76(1): 29–42.
  6. Borghi C, Tykarski A, Widecka K, et al. Expert consensus for the diagnosis and treatment of patient with hyperuricemia and high cardiovascular risk. Cardiol J. 2018; 25(5): 545–563.
  7. Borghi C, Perez-Ruiz F. Urate lowering therapies in the treatment of gout: a systematic review and meta-analysis. Eur Rev Med Pharmacol Sci. 2016; 20(5): 983–992.
  8. White WB, Saag KG, Becker MA, et al. CARES Investigators. Cardiovascular safety of febuxostat or allopurinol in patients with gout. N Engl J Med. 2018; 378(13): 1200–1210.
  9. Richette P, Latourte A, Bardin T. Cardiac and renal protective effects of urate-lowering therapy. Rheumatology (Oxford). 2018; 57(suppl_1): i47–i50.
  10. Kojima S, Matsui K, Ogawa H, et al. Rationale, design, and baseline characteristics of a study to evaluate the effect of febuxostat in preventing cerebral, cardiovascular, and renal events in patients with hyperuricemia. J Cardiol. 2017; 69(1): 169–175.
  11. Kimura K, Hosoya T, Uchida S, et al. FEATHER Study Investigators. Febuxostat Therapy for Patients With Stage 3 CKD and Asymptomatic Hyperuricemia: A Randomized Trial. Am J Kidney Dis. 2018; 72(6): 798–810.
  12. Zhang M, Solomon DH, Desai RJ, et al. Assessment of cardiovascular risk in older patients with gout initiating febuxostat versus allopurinol. Circulation. 2018; 138(11): 1116–1126.
  13. White WB. Gout, xanthine oxidase inhibition, and cardiovascular outcomes. Circulation. 2018; 138(11): 1127–1129.